- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Considerations & Factors For Initiating & Switching Antipsychotic Medications In Schizophrenia

Virtual Event – Considerations & Factors For Initiating & Switching Antipsychotic Medications In Schizophrenia
A Virtual Event for PsychU members in Arkansas, Kansas, Missouri, & Oklahoma.
This presentation will examine the essential factors for consideration when initiating and/or switching antipsychotic treatments in schizophrenia. Both general and specific factors unique to patient and medication are implemented into selecting the most appropriate switch strategy. Potential withdrawal and rebound effects during switch will be thoroughly discussed.
Featuring
-
Roger Sommi, PharmD, FCCP, BCPP
Associate Dean, UMKC School of Pharmacy – University of Missouri
-
Julleah Johnson, PhD (OPDC)
Senior Medical Science Liaison
Roger Sommi, PharmD, FCCP, BCPP is a paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.rnJulleah Johnson, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.rnrn
Related Events
Register
This event registration is closed.